Pharma Industry News

Gilead signs $300m deal with Dragonfly to advance immunotherapies

The partnership will make use of Dragonfly’s oncology and inflammatory disease research capabilities

Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]